ESC: Arrowhead Phase 3 SHASTA-3, -4 Data Demonstrate Plozasiran Reduced Acute Pancreatitis

  Plozasiran reduced triglycerides (TG) by 79% and 81% versus placebo in SHASTA-3 and SHASTA-4 across the broad sHTG population -

- More than 90% of plozasiran-treated patients achieved triglycerides below thresholds for AP risk, 500 mg/dL at Month 12, and more than half achieved triglycerides below 150 mg/dL -

- Plozasiran reduced cumulative acute pancreatitis (AP) events by 78% versus placebo in patients with TG above 500 mg/dL, with or without a prior history of AP -

- Greater absolute benefit of AP risk reduction was observed in patients at higher risk -

- In the highest-risk subgroup, patients with TG above 880 mg/dL and a prior history of AP, there was a 100% reduction in events versus placebo -

- Plozasiran demonstrated a favorable safety and tolerability profile, with overall treatment-emergent adverse events similar between plozasiran and placebo groups -

- Arrowhead plans to file a supplemental New Drug Application with the U.S. FDA by year-end 2026 and utilize a Priority Review Voucher -

- Detailed results presented at the European Society of Cardiology (ESC) Congress 2026 in Munich as a Hot Line Late-Breaking Science session -

https://ir.arrowheadpharma.com/news-releases/news-release-details/arrowhead-pharmaceuticals-presents-phase-3-shasta-3-and-shasta-4